BOCA RATON , Fla., March 22, 2018 (GLOBE NEWSWIRE) — Cleartronic, Inc., (OTCPINK:CLRI) announced that its subsidiary, VoiceInterop, Inc. has signed a non-binding Letter of Intent to acquire the assets of CanniPlus Global, Inc., a Florida based provider of medical CBD products.  Cleartronic’s Board of Directors is also considering other initiatives to unlock the value of VoiceInterop, Inc. 
Larry Reid, President of VoiceInterop commented: “We have signed a non-binding letter of intent to acquire CanniPlus Global, Inc., a Florida based provider of medical CBD products. This strategic acquisition, after it closes, will allow VoiceInterop to enter the retail and wholesale CBD market.”Reid closed by stating, “We will have additional announcement in the coming weeks outlining  the expected timetable for our acquisition of CanniPlus Global, our new strategic partnerships and our business plan. I look forward to providing all of this exciting news to our current and future shareholders.”Cannabidiol, also known as CBD are found throughout the seeds, stalk, and flowers of cannabis plants, including hemp and marijuana.  Because of the numerous positive medical benefits, people are continually seeking CBD products, creating a highly growth market in cannabidiol consumption.About Cleartronic, Inc.Cleartronic, Inc., a diversified holding Company, creates and acquires operating subsidiaries with the goal of manufacturing and selling products, services, and integrated systems to government agencies, business enterprises and the general public. In addition to its ongoing research and development projects, Cleartronic currently has two operating subsidiaries, ReadyOp Communications, Inc. and VoiceInterop, Inc. –, and Harbor StatementThis news release contains statements that involve expectations, plans or intentions (such as those relating to future business or financial results) and other factors discussed from time to time in the Company’s Securities and Exchange Commission filings. These statements are forward-looking and are subject to risks and uncertainties, so actual results may vary materially.